Glyphic Biotechnologies

Develops next-generation protein sequencing platform

New York City, New York, United States

About Glyphic Biotechnologies

Glyphic Biotechnologies focuses on advancing the field of proteomics by developing a unique protein sequencing platform. This platform enables researchers to analyze proteins in detail, which helps them understand biological processes and diseases better. The technology works by providing advanced sequencing services that allow for in-depth study of protein structures and functions. Unlike other companies in the biotechnology sector, Glyphic Biotechnologies emphasizes a next-generation approach to protein sequencing, aiming to deliver insights that are not available through traditional methods. The company's goal is to enhance biological and medical research by providing tools that facilitate a deeper understanding of proteins and their roles in health and disease.

New York City, New YorkHeadquarters
2021Year Founded
$41.9MTotal Funding
EARLY_VCCompany Stage
Biotechnology, HealthcareIndustries
11-50Employees

Benefits

Health Insurance
Dental Insurance
Vision Insurance
401(k) Company Match
Unlimited Paid Time Off
Commuter Benefits
Paid Maternity and Paternity Leave
Home Office Stipend
Wellness Program
Company Equity
Employee Stock Purchase Plan

Risks

Intellectual property disputes may arise in the competitive biotechnology sector.
Dependence on external funding poses financial risks if sources become insufficient.
Rapid technological advancements may render Glyphic's platform obsolete if not updated.

Differentiation

Glyphic's platform uses single-molecule technology for precise protein sequencing.
The company accelerates protein sequencing, reducing drug development times significantly.
Glyphic's technology surpasses mass spectrometry in analyzing complex protein mixtures.

Upsides

The proteomics market is projected to grow at a CAGR of 14.7% until 2030.
Glyphic received a $409K SBIR grant from NIH for its innovative technology.
Increased interest in single-molecule protein sequencing indicates potential collaborations.

Funding

Total raised$41.86 M
Latest valuation$165.90 M
StageEARLY_VC